Data from a trial in China of Gilead Sciences Inc.’s antiviral treatment remdesivir have been posted by accident online by the World Health Organization, showing that the treatment did not improve the condition of patients with severe COVID-19 or reduce the presence of the virus in the bloodstream.
The study also found the remdesivir arm produced more discontinuations due to adverse events, raising safety concerns.






